Tilia Fiduciary Partners’s Charles River Laboratories CRL Stock Holding History

Tilia Fiduciary Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9,189	Closed	-$1.9M	–	106
2024 Q2	$1.9M	Buy	9,189 +663	+8%	+$150K	1.48%	28
2024 Q1	$2.31M	Buy	8,526 +914	+12%	+$218K	1.87%	12
2023 Q4	$1.8M	Buy	7,612 +1,317	+21%	+$259K	1.67%	17
2023 Q3	$1.23M	Buy	6,295 +545	+9%	+$112K	1.28%	33
2023 Q2	$1.21M	Buy	5,750 +837	+17%	+$167K	1.08%	33
2023 Q1	$992K	Buy	4,913 +221	+5%	+$50.1K	0.95%	36
2022 Q4	$1.02M	Buy	4,692 +104	+2%	+$22.7K	0.98%	32
2022 Q3	$904K	Buy	4,588 +474	+12%	+$102K	0.91%	35
2022 Q2	$895K	Buy	4,114 +259	+7%	+$63.3K	0.85%	40
2022 Q1	$1.09M	Buy	3,855 +265	+7%	+$81.7K	0.93%	38
2021 Q4	$1.35M	Buy	+3,590	New	+$1.39M	1.09%	24

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Tilia Fiduciary Partners's CRL Position: Q3 2024 in Review

Tilia Fiduciary Partners sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 9,189 shares — an estimated $1.9M sold.

Tilia Fiduciary Partners first reported a position in CRL in Q4 2021 and held it in 11 quarters. The position peaked at $2.31M in Q1 2024. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

Tilia Fiduciary Partners reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
Tilia Fiduciary Partners sold 9,189 Charles River Laboratories shares in Q3 2024, an estimated $1.9M.
Tilia Fiduciary Partners first reported a position in Charles River Laboratories in Q4 2021 and held it in 11 quarters.
Tilia Fiduciary Partners's Charles River Laboratories position peaked at $2.31M in Q1 2024.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2024, filed 8 Oct 2024.